Nevertheless, the administration of tyrosine kinase inhibitors (TKI) such as imatinib and dasatinib in cases of MPAL with BCR-ABL rearrangement, has a significant impact on improving the prognosis of patients’ lifespans (4, 51). The gene discussed is BCR; the disease is mixed phenotype acute leukemia.